Kristen Stewart Uses Crutches at Academy Awards









02/24/2013 at 09:45 PM EST



That's an unexpected accessory!

Kristen Stewart attended the 85th Annual Academy Awards on Sunday sporting quite the fashion statement – crutches.

The On the Road actress was forced to use them to help her make her way onto the red carpet after she stepped on glass.

The star's makeup artist, Beau Nelson, tells PEOPLE she "cut the ball of her foot, quite severely on glass two days ago." But a true pro, Stewart, 22, managed to pose for photographs without any crutches, showing off her cream-colored Reem Acra gown. Nelson adds that Stewart is "a little bit of pain" and it was a scramble to find suitable flats!

While she isn't nominated for any Oscars, Stewart's film Breaking Dawn Part 2 did sweep the 33rd annual Golden Raspberry Awards – better known as the Razzies – with seven awards.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Iranians Claim to Capture Drone





TEHRAN (AP) — Iran’s Revolutionary Guards said Saturday that they had captured a foreign unmanned aircraft during a military exercise in southern Iran.




Gen. Hamid Sarkheili, a spokesman for the military exercise, said the guards’ electronic warfare unit spotted signals indicating that foreign drones were trying to enter Iranian airspace. General Sarkheili said experts took control of one drone’s navigation system and brought it down near the city of Sirjan, where the military drills began Saturday.


“While probing signals in the area, we spotted foreign and enemy drones which attempted to enter the area of the war game,” the official IRNA news agency quoted the general as saying. “We were able to get one enemy drone to land.”


General Sarkheili did not say whether the drone was American.


In Washington, a C.I.A. spokeswoman declined to comment on the report.


Iran has claimed to have captured several American drones, including an advanced RQ-170 Sentinel C.I.A. spy drone in December 2011 and at least three ScanEagle aircraft.


Read More..

Breaking Dawn - Part 2 Sweeps the Razzies









02/23/2013 at 10:00 PM EST







Taylor Lautner and Mackenzie Foy, in Breaking Dawn – Part 2


Andrew Cooper, SMPSP/Summit


Who's misérable now?

The Twilight Saga: Breaking Dawn – Part 2, Adam Sandler and Rihanna are among the "winners" of the 33rd annual Golden Raspberry Awards – the Razzies – which are not so much handed out as they are thrown at those who are voted as perpetrating Hollywood's worst achievements of the year.

Breaking Dawn – Part 2, the fifth and final installment in Stephenie Meyer's vampire saga, was recognized in seven categories, including worst picture.

The flick's Kristen Stewart was also cited as worst actress; Taylor Lautner, worst supporting actor; Lautner and 12-year-old Mackenzie Foy, worst screen couple; the entire cast, including Robert Pattinson, worst screen ensemble, and Bill Condon, worst director.

In addition, the film, which since opening last November has taken in more than $828 million at the box office, was named worst sequel.

Sandler, who last year monopolized the Razzies – and set a record by winning in 10 categories with the "comedy" Jack & Jill – this year got only two awards: for worst actor of the year and worst screenplay, both for That's My Boy.

Unlike the Oscars, which keep voting tallies a secret and will be handed out Sunday night during a very glamorous event, founder and Head RAZZberry John Wilson announced Razzie recipients Saturday night in the utilitarian Continental Breakfast Room of the Holiday Inn Express Hollywood Walk of Fame hotel, near (and yet so far from) the Dolby Theatre, home of the Academy Awards.

Wilson revealed to the press that although Rihanna, as worst supporting actress in the movie Battleship, won her Razzie by a landslide, worst screenwriter Sandler only beat the authors of Breaking Dawn by a single vote.

It's close shaves like that that really make or break the Razzies.

Breaking Dawn – Part 2 Sweeps the Razzies| Oscars 2013, The Razzies 2013, Movies, Battleship, That's My Boy, News Franchises, Individual Class, Adam Sandler, Kristen Stewart, Rihanna, Robert Pattinson

Adam Sandler, in That's My Boy, and Rihanna, in Battleship

Columbia; Universal

The 85th annual Academy Awards will air live on ABC starting at 7 p.m. ET/4 p.m. PT on Sunday, Feb. 24, from the Dolby Theatre in Hollywood.
Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Digital billboard company issues $100-million threat against L.A.









An outdoor advertising company fighting to preserve dozens of digital billboards across Los Angeles warned this week that it would seek "substantially" more than $100 million from City Hall if it is ordered to remove any electronic signs targeted in a recent court ruling.


In an 11-page letter sent Friday, Clear Channel Outdoor told Mayor Antonio Villaraigosa, City Atty. Carmen Trutanich and Council President Herb Wesson that its digital signs are "valuable assets that the city cannot attempt to take away without paying just compensation."


The letter comes two months after a three-judge panel struck down a 2006 legal settlement approved by the City Council allowing Clear Channel and CBS Outdoor to convert 840 existing billboards to digital formats. The company installed 79 digital signs before the settlement was blocked.








The 2nd District Court of Appeal ordered a lower court to invalidate all digital conversions permitted under the agreement. But Sara Lee Keller, Clear Channel's lawyer, warned that if the council instructs the company to turn off the signs, "it would be exposed to liability to Clear Channel for the fair market value of such signs, which substantially exceeds $100 million."


"While litigating these claims would be costly and time-consuming for all … we believe it is important to be clear about the consequences," wrote Keller, who contends that other factors make all of the company's signs legal.


The letter drew a sharp response from Summit Media, a competing sign company that successfully sued to block the 2006 agreement. Phil Recht, the company's attorney, said Clear Channel has "no regard for the rule of law."


"Clear Channel is trying to bully the city into submission so that they can continue to make hundreds of millions of dollars in illegal profits from these digital billboards two courts ruled to be illegal," he said.


Clear Channel sent its letter one day before neighborhood activists and outdoor-advertising lobbyists — including the company and its representatives — took part in a working group to discuss possible digital sign legislation. One proposal up for discussion would allow new digital billboards to be installed in exchange for removing a greater number of static billboards.


Summit promised to work with neighborhoods on digital sign issues, saying the technology diminishes quality of life. In recent years, it has described the original 2006 agreement as a "sweetheart deal" that gave CBS and Clear Channel hundreds of millions of dollars in revenue.


Since the ruling, Clear Channel has been waging a publicity campaign in favor of digital billboards, putting together an advocacy group to argue on its behalf and touting support for its signs from such groups as AIDS Project Los Angeles, Art Share L.A. and the Los Angeles Area Chamber of Commerce. Those groups, among others, have asked the state Supreme Court to take another look at the ruling that invalidated the 2006 digital sign pact, according to Clear Channel's letter.


Clear Channel and a handful of other billboard companies also have been contributing tens of thousands of dollars in recent weeks to Proposition A, which is on the March 5 ballot and would raise the sales tax rate to 9.5% from 9%. That measure, if passed, is expected to generate more than $200 million annually for the city budget.


Meanwhile, Lamar Advertising, which has proposed its own plan for converting signs to digital formats, has been spending $5,000 per candidate on outdoor advertising promoting the City Council campaigns of Councilman Joe Buscaino, Assemblymen Bob Blumenfield (D-Woodland Hills) and Gil Cedillo (D-Los Angeles), and former Assemblyman Felipe Fuentes, as well as the city controller campaign of Councilman Dennis Zine.


Friday's letter from Clear Channel was accompanied by a legal claim, a document submitted before the filing of a lawsuit. Clear Channel spokesman Jim Cullinan said his company sent it because it must provide 90 days' notice before filing an action in court.


"This letter gives notice, but we hope it doesn't come to litigation," he said.


david.zahniser@latimes.com





Read More..

BBC Portrayed as Top-Heavy, Bickering and Dysfunctional





LONDON — A senior press officer for the British Broadcasting Corporation darkly volunteers to “drip poison” to discredit a BBC reporter he suspects of having leaked embarrassing information. The woman in charge of the corporation’s news divisions accuses Newsnight, a public-affairs program she oversees, of being out of touch and “sneery” toward rival BBC shows.




And, as investigators seek to uncover why the corporation canceled a Newsnight broadcast alleging that a once-beloved BBC personality who had recently died had in fact been a serial pedophile who preyed on vulnerable girls, everyone involved is scrambling to deflect blame onto someone else.


These and other unflattering details about the inner workings of Britain’s public broadcaster emerged Friday when the BBC released some 3,000 pages of internal documents — e-mails, memos and transcripts of interviews — from an external investigation into why the program, about the BBC presenter Jimmy Savile, had been canceled.


In all, the documents painted a picture of a highly dysfunctional, top-heavy organization divided into discrete, rival factions, and weighed down by mistrust, poor communication, buck-passing and internecine squabbling.


There were no startling revelations; all those came out in the so-called Pollard report into the Savile affair, which was published in December and which concluded that there were deep structural problems in the BBC. But the supporting documents released Friday shed light on just what Nick Pollard, who prepared the report, meant by his scathing critique, said John Whittingdale, chairman of the House of Commons culture and media committee.


“It demonstrates the extent of unhappiness within the BBC structure, the frustration at the bureaucratic nature of the management, and the generally poor state of morale,” Mr. Whittingdale said in a television interview.


Referring to the fact that material in some of the newly released documents was blacked out, apparently because of concerns that it might give rise to lawsuits, Mr. Whittingdale added: “The fact that so much of the evidence can’t be published, because we are told the lawyers have advised it could be defamatory, in a sense tells its own story.”


Large portions of the testimony of Jeremy Paxman, a blunt-talking Newsnight host who is known for his testy and combative interview style, for instance, are blacked out in places where it appears he is about to make personal remarks about other people.


And in an annoyingly tantalizing instance, Peter Horrocks, director of global news, declares: “It is no secret that ...” What follows has been redacted, however, so that it is in fact a secret.


Lord McAlpine, a former Tory cabinet minister who, in another debacle at Newsnight, was unjustly accused of being a pedophile in a report that was broadcast, said that the BBC should not have left out any material. “The BBC is not the Secret Service, for Christ’s sake,” he told The Daily Telegraph.


But the BBC defended the redactions. Tim Davie, the acting director general, said that “97 percent plus of all the thousands of pages are out there.”


In an interview with an off-camera interlocutor that was broadcast on the BBC Web site, Mr. Davie continued: “We are not redacting or taking out material that is embarrassing or uncomfortable to the BBC. We have simply taken out stuff that external lawyers saw as a clear risk.”


He did not make himself available for interviews with other news organizations on Friday — indeed, no one from the BBC did. That strategy was roundly ridiculed by the broadcaster’s rivals.


On Twitter, Ben de Pear, editor of Channel 4 News, said that over his career he had successfully coaxed interviews out of Robert Mugabe of Zimbabwe and Mahmoud Ahmadinejad of Iran. “We are still trying for Tim Davie,” he said.


Much of the material focused on who said what to whom, and when, during Newsnight’s investigations into the allegations against Mr. Savile — and during the subsequent decision to cancel the broadcast. But there were also general interviews with many key figures in the corporation about what was wrong and how to fix it.


The testimony of Lord Patten, chairman of the BBC Trust, was particularly sharp, as he described the chaotic flow of information, the preponderance of high-ranking officials (the BBC had “more senior leaders than China,” he said) and the general mistrust within the corporation. “Is a lesson I should take from this that I can’t believe it when I’m told things by the next director general, that I have to query everything he says or the director of news says to me or whatever?” he asked rhetorically.


No, he said in response. “With the next director general I won’t — or his senior colleagues — I won’t begin every conversation on the assumption that he or she or they may not be telling me the whole truth,” he said. “I will want to be more convinced that there is a structure in place which ensures that the truth is being told.”


Lark Turner contributed reporting from London, and Matthew Purdy from New York.



Read More..

Courtney Lopez: Gia Thinks Our Dog Is Having a Baby




Celebrity Baby Blog





02/22/2013 at 01:00 PM ET



Courtney Lopez: Gia Thinks Dog Having Baby
Denise Truscello/Wireimage


Mario Lopez is a man of his word.


Following a December wedding, the EXTRA host declared he and wife Courtney would get to work expanding their family immediately — and he wasn’t kidding.


In January, the couple discovered they were indeed expecting.


“Mario and I are so excited to add to our family! I found out a month ago and surprised Mario with the good news at breakfast,” Courtney tells PEOPLE.


But the proud parents aren’t the only ones gearing up for a new addition. Big sister Gia Francesca, 2, already has babies on the brain.


“Gia kind of understands that there is a baby in my belly,” Courtney notes. “She also told me our dog Julio has a baby in his belly — so who knows!”

Despite a bumpy start — “I had a rough couple of weeks when I first found out,” she shares — the mom-to-be is feeling better and already sporting quite the blossoming belly. “I am showing so much faster this time around,” she says.


And with warmer weather on the way, Courtney will be swathing her bump in floor-length frocks — but plans on foregoing a few fashion ensembles from her past.


“I love being pregnant in the summer! I live in maxi dresses,” she says. “Looking back at my first pregnancy, there are certain things that I wore and I have no idea why. I looked horrible and I won’t do that again!”


Originally from Pittsburgh, the expectant mama is thrilled to have settled down with her growing family on the West Coast. Her only wish? That her children will one day enjoy a winter wonderland.


“I don’t miss the East Coast at all — especially the humidity,” she explains. “The one thing I do want my children to experience from an early age is snow. There is nothing like being a kid playing in the snow.”


– Anya Leon


Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Councilman's preferred successor holds edge in Westside district









When Los Angeles City Councilman Bill Rosendahl decided in October to retire and focus on battling cancer, he anointed Mike Bonin, his longtime chief of staff, as his preferred successor.


The March 5 primary election now seems Bonin's to lose.


Of four candidates seeking to represent Council District 11 — which includes Brentwood, Mar Vista, Venice and Westchester — Bonin has raised the most money ($380,000, including matching funds, more than four times the amount amassed by his nearest rival). The self-avowed "progressive activist" has also received hundreds of endorsements from politicians, business and labor leaders, environmental groups and residents.








"He's smart, he's a doer, and he's solution-oriented," said Austin Beutner, a conservative businessman and former mayoral hopeful who recently held a meet-and-greet event for Bonin in Pacific Palisades. "He's not an ideologue."


Bonin's three opponents — Frederick Sutton, 28, a part-time bartender and community activist; Tina Hess, 52, a prosecutor with the city attorney's office; and Odysseus Bostick, 36, a Westchester teacher and parent — all acknowledge the financial leader's sizable edge. But they say they're fed up with pothole-riddled streets, homeless encampments and out-of-control municipal expenditures. Bonin, they say, represents a politics-as-usual bureaucracy that has turned the City Council into what Sutton calls "a merry-go-round of lifetime politicians."


Having received $87,000 in donations and matching funds, Sutton sees his immediate goal as keeping Bonin from getting the simple majority of votes needed to seal victory in March. "Once you get into a runoff," Sutton said, "suddenly everything changes."


Bonin, 45, has unveiled plans to make Los Angeles more employer-friendly (extend the Internet tax exemption for Silicon Beach companies, support tax credits and reduce red tape for film operations) and to improve residents' access to City Hall through regular community meetings and technology ("Hikes with Mike" and "Mayberry meets the iPhone")


After receiving his bachelor's degree in U.S. history at Harvard University, Bonin worked as a newspaper reporter before entering politics. The Massachusetts native moved to the Los Angeles area in the early 1990s. He lives in Mar Vista with his partner, Sean Arian, a consultant.


A Gold's Gym regular who eats mostly raw foods, Bonin sports five tattoos, including a recycling symbol on his left shoulder that serves partly "as a symbol of getting sober and taking a life that had been trash and making it productive again." After long overdoing it on drugs and alcohol, Bonin said, he has been sober for 18 years.


The diverse Westside sector he seeks to represent is rife with vocal activists and hot-button issues: congestion, transit construction, an imbalance between jobs and housing, transients and the modernization of Los Angeles International Airport. Like Rosendahl, Bonin opposes separating the northern runways but is all for updating the airport.


Bonin said his 17 years in public service have prepared him.


He first worked in city government as legislative deputy, district director and deputy chief of staff for former Councilwoman Ruth Galanter. He then became deputy chief of staff and district director for Rep. Jane Harman, who represented many 11th district neighborhoods before retiring from Congress. He has been Rosendahl's chief deputy since 2005.


Elected in 2005 and 2009, Rosendahl, 67, was favored to win a third and final term before being diagnosed with advanced cancer last summer.


Bonin said he has been inspired by his boss' spirit and resilience after months of grueling cancer treatments. "He's got the level of energy back that most of the staff finds exhausting to be around," Bonin told a group of elderly residents one recent afternoon.


Marcia Hanscom, a wetlands activist, said she endorsed Bonin after hearing his ideas for bringing government closer to the people and promoting nature in the city.


"He's got good values and instincts, and he also knows the inner workings of City Hall and its bureaucracy," she said in an email. "If he does as he says — getting and staying close to the constituents — he will not be so captured by City Hall as some think he is."


martha.groves@latimes.com


Times researcher Maloy Moore contributed to this report.





Read More..